Get the Daily Brief
Latest Biotech News
Chugai buys kidney biotech – ICER flags rising launch prices
Chugai Pharmaceutical completed an acquisition of a kidney‑focused biotech (terms reported in industry outlets), expanding its nephrology portfolio. Separately, the Institute for Clinical and...
FDA finds unauthorized API warehouse in India: Animal infestations cited
The FDA reported discovering an unauthorized warehouse holding active pharmaceutical ingredients and finished drugs linked to Indian generic manufacturer Hetero Labs; the inspection uncovered...
Biogen bankrolls Vanqua drug: $70M upfront for C5aR1 program
Biogen struck an exclusive licensing deal with Vanqua Bio, paying $70 million up front for global rights to a preclinical C5aR1 antagonist that targets innate immune signaling. The agreement gives...
Lilly buys Adverum gene‑therapy assets – strategic push into AAV space
Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum’s assets, reinforcing the company’s commitment to AAV‑based retinal and ocular programs. The deal positions Lilly to...
FDA greenlights elinzanetant: nonhormonal option for menopausal hot flashes
The U.S. Food and Drug Administration approved elinzanetant, a nonhormonal agent shown in multinational trials to reduce the frequency and severity of menopausal hot flashes and night sweats....
Inhibrx posts win in rare bone cancer – phase II meets endpoint
Inhibrx reported positive registrational phase II results for ozekibart in advanced or metastatic, unresectable chondrosarcoma, meeting its primary endpoint with a statistically significant...
Tango PRMT5 data satisfy — paves way to pivotal pancreatic trial
Tango Therapeutics disclosed early clinical data for its next‑generation MTA‑cooperative PRMT5 inhibitor vopimetostat (TNG‑462) that showed activity in MTAP‑deleted tumors, including pancreatic...
Regeneron shelves 2seventy‑acquired CAR‑T – strategic pipeline pruning
Regeneron announced it will discontinue development of bbT369, a CAR‑T candidate acquired from 2seventy bio, halting plans to advance the asset into a planned phase II study. The company described...
LNP shapes mapped: structural study ties form to delivery efficiency
A multi‑institutional team from the University of Pennsylvania, Brookhaven National Laboratory and industry partners published a biophysical characterization of four lipid nanoparticle (LNP)...
Teamwork raced to make Baby KJ’s CRISPR therapy: months‑long feat
A coordinated collaboration between clinicians, academic labs and industry CDMOs produced a bespoke CRISPR‑based therapy for an infant with a lethal urea cycle disorder in a matter of months....
Nanopore cfDNA assay detects tissue‑of‑origin and pathogens in critical‑care plasma
Researchers demonstrated that nanopore sequencing of plasma cell‑free DNA can simultaneously capture tissue‑of‑origin signals and identify pathogenic sequences in critically ill patients. The...
Deep learning speeds antibiotic discovery — new computational scaffolds emerge
A Nature Biotechnology–reported effort showed deep‑learning models can accelerate identification of novel antibacterial scaffolds by mining chemical and biological data to prioritize candidates...
Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical immunology asset
Biogen announced an exclusive worldwide license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and up to $990 million in milestone payments. The company will lead all...
Lilly rescues Adverum: buys cash‑strapped gene‑therapy developer for its phase‑3 asset
Eli Lilly agreed to acquire Adverum in a deal that secures the AAV-based gene therapy ixo‑vec, currently in a Phase 3 study for wet age‑related macular degeneration (wAMD). The purchase price is...
Inhibrx posts registrational win: ozekibart hits primary endpoint in chondrosarcoma
Inhibrx reported top‑line results from a registrational Phase II, showing ozekibart (INBRX‑109) achieved a statistically significant improvement in median progression‑free survival for advanced or...
Tango’s PRMT5 data clear way to pivotal pancreatic study — company to advance vopimetostat
Tango Therapeutics unveiled Phase I/II data for vopimetostat (TNG‑462), an MTA‑cooperative PRMT5 inhibitor, reporting response rates and progression‑free survival in MTAP‑deleted pancreatic ductal...
Gepotidacin’s approval for UTIs: fluoroquinolone‑alternative gets greenlight, gonorrhea review continues
Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received FDA approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and remains under FDA review...
LNP structure and rapid CRISPR manufacturing: delivery tech meets bespoke gene cures
Two studies surfaced this week that target bottlenecks in nucleic acid therapeutics: a Nature Biotechnology report mapped diverse lipid nanoparticle (LNP) shapes and linked structural differences...
Remix shows first tumor shrinkage with small‑molecule mRNA degrader in rare cancer
Remix Therapeutics disclosed the initial signs of tumor shrinkage in a patient with a rare salivary gland cancer treated with its small‑molecule mRNA degrader platform. The company reported early...
Merus widens oncology reach: petosemtamab shows activity in colorectal cancer
Merus released updated clinical data for petosemtamab showing responses across multiple lines of colorectal cancer, signaling potential use beyond its development focus in head and neck tumors....